The Life Sciences team advised ARTBIO in its exclusive strategic collaboration agreement with AlphaGen Therapeutics. Under the terms of the exclusive agreement, AlphaGen will use ARTBIO’s AlphaDirect™ isotope isolation technology to generate 212Pb, a unique isotope without a global supply. AlphaGen will also receive rights to develop and commercialize AB001, a clinical-stage alpha radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), in Greater China which includes mainland China, Hong Kong, Macau, and Taiwan. Furthermore, AlphaGen will have the right to use AlphaDirect™ to develop 212Pb RLTs against additional targets. The companies also agreed to an option mechanism for each other’s programs to enable rapid global commercialization. For additional details on the agreement, please read the press release.
Additionally, ARTBIO announced in January 2024 that it had entered into three agreements to produce its lead asset AB001, a Lead-212 (212Pb)-based radiopharmaceutical candidate, for the treatment of prostate cancer. These include:
- Strategic manufacturing and supply agreement with Eckert & Ziegler Strahlen- und Medizintechnik AG under which Eckert & Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies, using ARTBIO’s proprietary AlphaDirectTM (Lead-212) Pb-212 isolation technology.
- New partnership agreement with SpectronRx under which SpectronRx will use its state-of-the-art facilities in Indiana to serve as a contract developer and manufacturer to manufacture and produce clinical supplies of AB001.
- Manufacturing and supply agreement with PharmaLogic Holdings Corp. under which PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phases I and II clinical trials of AB001 from PharmaLogic’s facility in New York, using ARTBIO’s proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology.
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb-212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
The Goodwin team representing ARTBIO in the above transactions was led by Can Cui and included Xiaowei Wu, Susan Lee, Richard Matheny III and Gozde Guckaya.